Katja Rosenkranz

Experience

1. V-Bio VenturesPartnercurrent2019 — presentGent. Belgium
2. V-Bio VenturesPrincipal2016 — 2018Gent, Belgium
3. Trim TherapeuticsInterim CEO; Director Trim Txcurrent2024 — present
4. Jay TherapeuticsDirector Jay Therapeuticscurrent2021 — presentGhent, Flemish Region, Belgium
5. ExeVirBoard Membercurrent2020 — present
6. dualyxBoard Membercurrent2020 — present
7. AgomAb TherapeuticsMember of the Board2019 — 2023Gent, Belgium
8. AgomAb TherapeuticsInterim CEO AgomAb Therapeutics2018 — 2019Gent, Belgium
9. Ascenion GmbH, Patent Management AgenturSenior Investment and Project Manager2011 — 2016Greater Munich Metropolitan Area
10. Dr. Katja Rosenkranz & Rainer Friedl GbrManaging Director2007 — 2015
11. Hepa WashCBO/CFO2007 — 2011Greater Munich Metropolitan Area
12. PolyTechnos Venture PartnersInvestment Analyst / Associate2003 — 2007Greater Munich Metropolitan Area
13. Max Planck Institute of NeurobiologyPH.D. Student1998 — 2002Greater Munich Metropolitan Area

Education

1. IBSTExecutive MBA Medical Devices & Healthcare Management
2. University Witten / HerdeckeMaster's Degree, Biochemistry
3. University Witten/Herdecke & MPI Neurobiology, MunichPhD Biochemistry

Skills & more

• Executive MBA Medical Devices and Healthcare Management — FIBAA, ACQUIN

From Katja's professional profile.

Shared employers

Also worked at V-Bio Ventures5

CTChristina TakkeManaging Partner at V-Bio VenturesWBWillem BroekaertManaging Partner at V-Bio VenturesSMShelley MargetsonManaging Partner at V-Bio VenturesWCWard CapoenPartner at V-Bio VenturesMFMathias FalcenbergVenture Partner at V-Bio Ventures

Also worked at ExeVir3

HNHalina NovakPrincipal at Fund+DJDr. Jeanne BolgerAdvisor at Apollo Health VenturesJBJeanne BolgerVenture Partner at Seroba Life Sciences

Also worked at AgomAb Therapeutics2

FVFelice Verduyn - Van WeegenPartner at EQT Life SciencesMCMatthieu CoutetPartner, Biovelocita Strategy at Sofinnova Partners

Also worked at PolyTechnos Venture Partners2

EAEric AchtmannAdvisory Board at Arowana PartnersSASophie Ahrens-GruberInvestor at Acton Capital